AstraZeneca signs MoU with Indian Diabetes Research Society (RSSDI) to empower 1 crore Indian diabetic patients by 2023 – Tech

is near 8 crores Diabetes patients IndiaThe need to build awareness and research-based effort to provide much needed support for early detection and treatment of diabetes will go a long way in reducing the uncontrolled incidence of the disease and related complications.

Bangalore, India, November 26, 2020 / PRNewswire / – AstraZeneca Pharma India Limited, a science-led biopharmaceutical company, today signed a memorandum of understanding with the Research Society for Studies of Diabetes. India (RSSDI). The purpose of this MoU is to create a right awareness of diabetes in people and driving to prevent complications from uncontrolled incidence of the disease.

RSSDI is the largest organization among diabetes health care professionals and researchers Asia Physicians, diabetologists, endocrinologists, as well as paramedical personnel with about 6000 members. The organization has played an important role in extensive research on diabetes, as well as continuing diabetes education initiatives. India. As a core aspect of this dual association, AstraAnica unveiled a campaign – Beyond Sugar, to develop a three-year patient awareness program to benefit 1 crore People living with diabetes across the country. This initiative will empower patients / caregivers to interact around diabetes and make informed decisions about the management of the disease.

The International Diabetes Foundation Atlas on Diabetes shows that 1 in 11 people in the South Asia Have more diabetes India Will be around 11.5 crores Diabetes patients by 2030. 10% to 15% of the common people have diabetes, a recent study reported that 44% of patients hospitalized for heart failure (HF) have type 2 diabetes, which links the relationship between diabetes and HF it shows. HF is a major health problem India With a mortality rate of 20% –30% after admission. Chronic kidney disease is associated with significant patient death and increased risk of heart failure. Therefore, it is important that diabetes be controlled to reduce the incidence of HF and CKD. India.

Dr. Anil Kukreja, Vice President – Medical Affairs and Regulatory, AstraZeneca India, Said, “AstraZeneca has always been at the forefront of enabling patient-centric solutions for the management of non-communicable diseases. Despite currently available therapy, awareness levels among the public are relatively low, resulting in uncontrolled diabetes and additional heart and kidney complications. A partnership between AstraZeneca and RSSDI will go a long way in supporting patient-centric digital awareness campaigns and programs to raise awareness about diabetes and its complications so that they act quickly to manage or even prevent complications To do it ”.

DrBanshi Sabu, President-RSSDI and Organizing President 2020, He said, “The partnership between RSSDI and AstraZeneca will increase the level of awareness about diabetes and its complications. Our vision is to touch 1 crore Lives in India Over the next three years through this digital patient-centric approach. In the COVID era, this digitally-driven initiative will empower patients / caregivers to better interact with their doctors about the disease and make informed decisions in the management of diabetes. All of this will end with a holistic and early cardio-renal-focused 2-type diabetes management approach. “

Dr Sanjay Aggarwal, Secretary- RSSDI 2020, Said, “Being the largest organization among diabetes doctors and researchers Asia, RSSDI is always focused on increasing diabetes and patient outcomes with constant research and innovative solutions. Beyond Sugar is a patient-centric initiative that will play an important role with our RSSDI state chapters to raise awareness using social media and digital platforms. With the support of AstraZeneca, we aim to reach out to patients, the community, and HCP to raise awareness about diabetes and help patients start conversations about the prevention of complications in diabetes. “

About AstraZeneca Pharma India Limited

AstraZeneca is a global, science-based biopharmactic company focused primarily on the discovery, development, and commercialization of prescription drugs for the treatment of diseases in three medical areas – oncology, cardiovascular, renal and metabolicism, and respiratory. AstraZeneca operates in more than 100 countries, and its innovative drugs are used by millions of patients worldwide.

AstraZeneca Pharma India Limited (AZPIL) was established in 1979 and marks its 40th year of long-standing commitment in patients India. It is headquartered in Bengaluru, Karnataka. AstraZeneca India has a workforce of over 1400 employees across the country who are committed to delivering great medicines to patients through innovative science and global excellence in development and commercialization. for more information please visit: www.astrazeneca.com/india

Content is by PR Newswire. Tech Media is not responsible for the content provided or any link related to this content. Tech Media is not responsible for the accuracy, timeliness or quality of content.

Most Popular

To Top
// Infinite Scroll $('.infinite-content').infinitescroll({ navSelector: ".nav-links", nextSelector: ".nav-links a:first", itemSelector: ".infinite-post", loading: { msgText: "Loading more posts...", finishedMsg: "Sorry, no more posts" }, errorCallback: function(){ $(".inf-more-but").css("display", "none") } }); $(window).unbind('.infscr'); $(".inf-more-but").click(function(){ $('.infinite-content').infinitescroll('retrieve'); return false; }); $(window).load(function(){ if ($('.nav-links a').length) { $('.inf-more-but').css('display','inline-block'); } else { $('.inf-more-but').css('display','none'); } }); $(window).load(function() { // The slider being synced must be initialized first $('.post-gallery-bot').flexslider({ animation: "slide", controlNav: false, animationLoop: true, slideshow: false, itemWidth: 80, itemMargin: 10, asNavFor: '.post-gallery-top' }); $('.post-gallery-top').flexslider({ animation: "fade", controlNav: false, animationLoop: true, slideshow: false, prevText: "<", nextText: ">", sync: ".post-gallery-bot" }); }); });